Diazepam binding inhibitor-like immunoreactivity (DBI-LI) in human CSF: Correlations with neurological disorders

https://doi.org/10.1016/0022-510X(88)90257-2Get rights and content

Abstract

Cerebrospinal fluid (CSF) levels of the anxiogenic neuropeptide diazepam binding inhibitor (DBI) were determined by radioimmunoassay in 281 patients who underwent evaluation for neurological problems. Serial dilution curves and reverse-phase high pressure liquid chromatography showed that the immunoreactive material in CSF behaved just as authentic DBI extracted from human brain. Furthermore in the assay there was no evidence of interference from CSF samples deprived of DBI by immunoaffinity. In 82 patients with no evidence of major lesions in the central nervous system, who acted as controls, the CSF DBI content was shown to be age- and sex-related. No correlation was observed with the CSF protein concentration. In patients with different types of dementia, the levels of CSF DBI were significantly increased in a group with normal pressure hydrocephalus. No significant differences were found between Alzheimer's disease, multi-infarct dementia, or dementia with Parkinson's disease and controls. In non-demented patients with Parkinson's disease the levels of DBI were increased in a subgroup with depressive disturbances whereas no difference was observed in the non-depressed cases. The content of DBI was markedly reduced in 5 cases with olivopontocerebellar atrophy and in 4 with spinocerebellar ataxia. In all the other disorders studied the levels of DBI were similar to or slightly lower (multiple sclerosis) than those of the controls. The origin of DBI in cerebrospinal fluid is uncertain; a number of various possibilities are discussed concerning the proposed role of DBI as modulator of brain GABAergic transmission.

References (79)

  • M.F. Folstein et al.

    Mini Mental State

    J. Psychiat. Res.

    (1975)
  • S. Govoni et al.

    Impairment of brain neurotransmitter receptors in aged rats

    Mech. Aging Dev.

    (1980)
  • O.H. Lowry et al.

    Protein measurements with the Folin phenol reagent

    J. Biol. Chem.

    (1951)
  • M.B. Meyers et al.

    Aging: effect on the interaction of ethanol and pentobarbital with the benzodiazepine-GABA-receptor-ionophore complex

    Brain Res.

    (1985)
  • E.K. Perry et al.

    Neurotransmitter enzyme abnormalities in senile dementia

    J. Neurol. Sci.

    (1977)
  • M. Shoyab et al.

    Isolation and characterization of a putative endogenous benzodiazepinoid (endozepine) from bovine and human brain

    J. Biol. Biochem.

    (1986)
  • H.M. Van Praag

    Depression

    Lancet

    (1982)
  • Y. Agid et al.

    Biochemical substrates of mental disturbances in Parkinson's disease

  • H. Alho et al.

    Diazepam Binding Inhibitor: a neuropeptide located in selected neuronal populations of rat brain

    Science

    (1985)
  • American Psychiatric Association

    Diagnostic and Statistical Manual of Mental Disorders

    (1980)
  • M.L. Barbaccia et al.

    Diazepam binding inhibitor: a brain neuropeptide present in human spinal fluid

    Studies in depression, schizophrenia and Alzheimer's disease

    Arch. Gen. Psychiat.

    (1986)
  • J.R. Barker et al.

    Pentabarbitone pharmacology of mammalian central neurons grown in tissue cultures

    J. Physiol.

    (1978)
  • A.T. Beck et al.

    An inventory for measuring depression

    Arch. Gen. Psychiat.

    (1961)
  • R. Bleier

    The relations of ependyma to neurons and capillaries in the hypothalamus: A Golgi-cox study

    J. Comp. Neurol.

    (1971)
  • J. Bormann et al.

    Neuropeptide modulation of GABA receptor Cl channels

    Regul. Peptides

    (1985)
  • J. Bormann et al.

    Mechanism of anion permeation through channels gated by glycine and γ-aminobutyric acid in mouse cultured spinal neurons

    J. Physiol.

    (1987)
  • P. Bovolin et al.

    Anatomical localization of DBI and ODN like immunoreactivity in rat brain

    Soc. Neurosci. Abstr.

    (1987)
  • C. Braestrup et al.

    Interaction of convulsive ligands with benzodiazepine receptors

    Science

    (1982)
  • R. Cantello et al.

    Mood changes associated with “end of dose deterioration” in Parkinson's disease: a controlled study

    J. Neurol. Neurosurg. Psychiat.

    (1986)
  • E. Costa et al.

    Evidence for the involvement of GABA in the action of benzodiazepines: Studies in rat cerebellum

  • E. Costa et al.

    Cotransmission at GABAergic synapses

  • S.G. Enna et al.

    Cerebrospinal fluid gamma-aminobutyric-acid and variations in neurological disorders

    Arch. Neurol. (Chic.)

    (1977)
  • C. Ferrarese et al.

    Subcellular localization and neuronal release of diazepam binding inhibitor

    J. Neurochem.

    (1987)
  • T.N. Ferraro et al.

    Further characterization of in vitro conditions appropriate for GABA determination in human CSF: impact of acid deproteinization and freeze/thaw

    J. Neurochem.

    (1983)
  • P. Ferrero et al.

    Increase in the B max of gamma-aminobutyric acid A recognition sites in brain regions of mice receiving diazepam

  • P. Ferrero et al.

    Study of an octadecaneuro-peptide derived from DBI: biological activity and presence in rat brain

  • P. Ferrero et al.

    Measurements of DBI-LI in brain, CSF and plasma of human subjects

    Psychiat. Res.

    (1986)
  • H.C. Fibiger

    The neurobiological substrates of depression in Parkinson's disease: a hypothesis

    Can. J. Neurol. Sci.

    (1984)
  • Cited by (30)

    • Neurosteroid biosynthetic pathways changes in prefrontal cortex in Alzheimer's disease

      2011, Neurobiology of Aging
      Citation Excerpt :

      Our findings suggest that in early AD, there is an attempt to increase the biosynthesis of neurosteroids and neuroactive steroids through increased mitochondrial import of cholesterol. Previously, measurements of enzyme levels in cerebrospinal fluid (CSF) showed that DBI protein levels were increased in AD patients with severe cognitive impairment (Ferrarese et al., 1990) although other studies failed to find any increase (Barbaccia et al., 1986; Ferrero et al., 1988), a discrepancy which may be related to differences in AD cognitive impairment and age range of the subjects. Second, we found increased expression of AKR1C2 mRNA in PFC of AD patients starting from BR 3.

    • Neurosteroid and GABA-A receptor alterations in Alzheimer's disease, Parkinson's disease and multiple sclerosis

      2011, Neuroscience
      Citation Excerpt :

      DBI promotes the loading of cholesterol into the mitochondrion, which is a rate-limiting step for the whole neurosteroid biosynthetic pathway, and does so both directly and via interaction with TSPO. Previously, measurements of enzyme levels in cerebrospinal fluid (CSF) showed that DBI protein levels were increased in AD patients with severe cognitive impairment (Ferrarese et al., 1990) although other studies failed to find any increase (Barbaccia et al., 1986; Ferrero et al., 1988), a discrepancy which may be related to differences in the degree of cognitive impairment and the age range of the subjects. StAR protein was also markedly increased in both the cytoplasm of hippocampal pyramidal neurons and in the cytoplasm of other non-neuronal cell types in the brains of female AD patients, when compared with age-matched controls (Webber et al., 2006).

    • Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: A pathogenetically based approach

      2010, Neurobiology of Disease
      Citation Excerpt :

      Cell death may on the other hand result in increased levels of neuropeptides through the release of peptides from damaged brain tissue (Espino et al., 1995). Raised CSF peptide levels have been demonstrated for diazepam binding inhibitor (DBI) (Ferrero et al., 1988a,b) and des-ala-somatostatin (Strittmatter et al., 1996). Several neuropeptides have been reported only once and the results of some neuropeptide studies led to conflicting data (Dupont et al., 1982; Espino et al., 1995; Jolkkonen et al., 1986; Strittmatter et al., 1996; Strittmatter and Cramer, 1992; Unger et al., 1988).

    View all citing articles on Scopus
    View full text